Journal
CURRENT OPINION IN PULMONARY MEDICINE
Volume 21, Issue 2, Pages 133-141Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCP.0000000000000145
Keywords
airway disease; chronic bronchitis; chronic obstructive pulmonary disease; genetics; N-acetylcysteine
Categories
Funding
- NHLBI [K23HL094696]
- Boehringer Ingelheim
- GlaxoSmithKline
- Roche Pharmaceuticals
- AstraZeneca
- MedImmune
- Pearl
- Actelion
- Forest
- Aeris Therapeutics
- Pulmonx
- PneumRx
- Temple University
Ask authors/readers for more resources
Purpose of review Chronic obstructive pulmonary disease (COPD) is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis is associated with multiple clinical consequences, including hastening lung function decline, increasing risk of exacerbations, reducing health-related quality of life, and possibly raising all-cause mortality. Recent data suggest greater elucidation on the risk factors, radiologic characteristics, and treatment regimens. Our goal was to review the literature on chronic bronchitis that has been published in the past few years. Recent findings A growing body of literature that more carefully describes environmental risk factors, epidemiology, and genetics associated with chronic bronchitis. In addition, as computed tomography technology continues to improve, the radiologic phenotype associated with chronic bronchitis is better understood. Summary With these new data, the clinician can recognize the newly described risk factors and the associated phenotype for chronic bronchitis and entertain new treatment options for this high-risk population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available